BIOMARIN PHARMACEUTICAL INC — Director's Dealing 2018

Jan 5, 2018

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BIOMARIN PHARMACEUTICAL INC (BMRN)
CIK: 0001048477
Period of Report: 2018-01-02

Reporting Person: FUCHS HENRY J (President, Worldwide R&D)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2018-01-02	Common Stock	M	5000	$26.49	Acquired	138976	Direct
2018-01-02	Common Stock	M	10000	$37.46	Acquired	148976	Direct
2018-01-02	Common Stock	S	15000	$89.2267	Disposed	133976	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2018-01-02	Stock Option (right to buy Common Stock)	$26.49	M	5000	Disposed	2021-05-11	Common Stock (5000)	Direct
2018-01-02	Stock Option (right to buy Common Stock)	$37.46	M	10000	Disposed	2022-05-07	Common Stock (10000)	Direct

Footnotes

F1: Trade made pursuant to a 10b5-1 plan executed on May 9, 2017.

F2: Amount of securities beneficially owned has been updated from the reporting person's prior report to: a) exclude 1,435 shares as previously reported in the Form 4 Amendment filed with the S.E.C. on 10/13/2017; and b) exclude 1,011 shares inadvertently included in prior reports based on a reconciliation with the Company's records.

F3: The price in column 4 is the weighted average price. The price actually received ranged from $88.84 to $90.00. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price.

F4: Reflects the number of options outstanding after the transactions from this specific stock option grant.